A general approach for sample size calculation for the three-arm 'gold standard' non-inferiority design

被引:26
作者
Stucke, Kathrin [1 ]
Kieser, Meinhard [1 ]
机构
[1] Heidelberg Univ, Inst Med Biometry & Informat, D-69120 Heidelberg, Germany
关键词
non-inferiority; three-arm trial; sample size calculation; optimal allocation; multiple comparisons; intersection-union test; PLACEBO-CONTROLLED TRIAL; BINARY END-POINTS; ESTABLISHING EFFICACY; MULTIPLE-SCLEROSIS; STATISTICS; DIFFERENCE; ISSUES;
D O I
10.1002/sim.5461
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In the three-arm gold standard non-inferiority design, an experimental treatment, an active reference, and a placebo are compared. This design is becoming increasingly popular, and it is, whenever feasible, recommended for use by regulatory guidelines. We provide a general method to calculate the required sample size for clinical trials performed in this design. As special cases, the situations of continuous, binary, and Poisson distributed outcomes are explored. Taking into account the correlation structure of the involved test statistics, the proposed approach leads to considerable savings in sample size as compared with application of ad hoc methods for all three scale levels. Furthermore, optimal sample size allocation ratios are determined that result in markedly smaller total sample sizes as compared with equal assignment. As optimal allocation makes the active treatment groups larger than the placebo group, implementation of the proposed approach is also desirable from an ethical viewpoint. Copyright (C) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:3579 / 3596
页数:18
相关论文
共 33 条
[21]  
Lewis JA, 2005, BIOMETRICAL J, V47, P787, DOI 10.1002/bimj.200510182
[22]   A group sequential type design for three-arm non-inferiority trials with binary endpoints [J].
Li, Gang ;
Gao, Shan .
BIOMETRICAL JOURNAL, 2010, 52 (04) :504-518
[23]  
Mehrotra DV, 2005, BIOMETRICAL J, V47, P794, DOI 10.1002/bimj.200510183
[24]  
Mielke M, THE ASSESSMENT AND P
[25]   The assessment of non-inferiority in a gold standard design with censored, exponentially distributed endpoints [J].
Mielke, Matthias ;
Munk, A. ;
Schacht, A. .
STATISTICS IN MEDICINE, 2008, 27 (25) :5093-5110
[26]   Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study [J].
Nierenberg, Andrew A. ;
Greist, John H. ;
Mallinckrodt, Craig H. ;
Prakash, Apurva ;
Sambunaris, Angelo ;
Tollefson, Gary D. ;
Wohlreich, Madelaine M. .
CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (02) :401-416
[27]   Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo [J].
Pigeot, I ;
Schäfer, J ;
Röhmel, J ;
Hauschke, D .
STATISTICS IN MEDICINE, 2003, 22 (06) :883-899
[28]   A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis [J].
Polman, CH ;
O'Connor, PW ;
Havrdova, E ;
Hutchinson, M ;
Kappos, L ;
Miller, DH ;
Phillips, JT ;
Lublin, FD ;
Giovannoni, G ;
Wajgt, A ;
Toal, M ;
Lynn, F ;
Panzara, MA ;
Sandrock, AW .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09) :899-910
[29]   Statistical strategies for the analysis of clinical trials with an experimental treatment, an active control and placebo, and a prespecified fixed non-inferiority margin for the difference in means [J].
Roehmel, Joachim ;
Pigeot, Iris .
STATISTICS IN MEDICINE, 2011, 30 (26) :3162-3164
[30]   A Comparison of Multiple Testing Procedures for the Gold Standard Non-Inferiority Trial [J].
Roehmel, Joachim ;
Pigeot, Iris .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2010, 20 (05) :911-926